Title: HIV Transplant Investigators Meeting: Introduction and Welcome
1HIV Transplant Investigators MeetingIntroduction
and Welcome
800 810
- Nancy Bridges, NIH
- Peter Stock, UCSF
- Michelle Roland, UCSF
2Meeting Objectives
- 810 820
- Michelle Roland
- Administrative Issues
- Protocol Review
- Policy
- Other
3Objectives Administrative Issues
- U01 and Terms and Conditions of Award
- Subcontracts IRB and regulatory issues
- Site visits pre-start up
- Steering and Operations Committee Publications
and Presentations Subcommittee - Data Management
- Adverse Events Reporting
4Objectives Protocol Issues
- Study Aims
- Inclusion and Exclusion Criteria
- Schedule of Events and Sub-Study Clusters
- Medication Regimens and Drug Interactions
- Immunosuppressants, ARVs, and Prophylaxis
- Clinical Issues
- HCV, HBV, and Rejection
- Stopping Rules
5Meeting Objectives Policy and Other Issues
- Publications and Media Policy
- Reimbursement
- Donor Consent
- Complete Good Clinical Practices (GCP) Training
- Resources on the EMMES Study Website
- Community Advisory Board
- Coordinator Meeting Tomorrow
- More GPC training
- Data entry
- Specimen shipping and tracking
- Anal HPV swabs and follow-up (UCSF, U Maryland,
Mt. Sinai liver, Columbia, Cedars-Sinai) -
6Budget and Regulatory Issues
- 820 830
- Michelle Roland
- IRB Approvals
- Regulatory Documents to NIH
- Site Visits Pre-Start Up
- Subcontract Conditions (Milestones)
7Subcontract Requirements
- Milestone 1, first 15 Centers will get initial
funding - IRB Approvals to Natasha Tomilin
- Regulatory Documents to Natasha Tomilin
- Milestone 2, to renew subcontract, must
demonstrate productivity (screening, enrollment
and transplantation), data quality and regulatory
adherence. - These factors will be reviewed approximately
every 6 months from the time of initial funding. - Concerns will be communicated as soon as
identified
8Good Clinical Practices Training
- 830 1000
- Barbara Pennington
9Study Aims
- 1015 1025
- Peter Stock
- Primary Aims
- Secondary Aims
10Specific Aims
- 2 hypothesis-driven aims
- Patient survival
- Graft survival
- 4 exploratory aims
11Primary Aim 1Evaluate the impact of
immunosuppression on patient survival
- Hypothesis Liver and kidney transplant
recipients will have survival rates comparable to
other patient groups without HIV infection that
are currently considered acceptable transplant
candidates.
12Control Groups
- We anticipate, as with older subjects, that
transplantation of HIV patients is an acceptable
but high risk procedure. - We expect survival may be less than that of age
matched controls but that results should be
similar to those seen in other poor prognosis
groups (e.g. diabetics, hospitalized patients,
etc). - The gt65 year old normative group was selected
because it is relatively common (7 of livers)
and represents many organ failure causes.
13 - Also age-race-donor source-matched controls from
the national registry. - The effect of transplantation on mortality will
be examined by comparing the mortality rate of
subjects awaiting transplant to those receiving
an allograft.
14Primary Aim 2Evaluate the impact of HIV
infection and HAART on graft survival
- Hypothesis 1 HIV liver and kidney transplant
recipients will have graft survival rates
comparable to other patient groups without HIV
infection that are currently considered
acceptable candidates.
15Graft survival in HBV/HCV co-infection
- Hypothesis 2 HIV liver transplant recipients
co-infected with hepatitis B or C will have graft
survival comparable to other patient groups with
the same viral hepatitis infections but without
HIV infection that are currently considered
acceptable candidates.
16Graft survival in HIVAN
- Hypothesis 3 HIV kidney transplant recipients
with HIV nephropathy (HIVAN) will have recurrence
of HIVAN resulting in impaired renal function and
graft survival despite the use of HAART.
17Secondary Aim 1 Explore the impact of
post-transplant immunosuppression on changes in
CD4 T cell counts and HIV-1 RNA levels.
18Rationale
- Immunosuppression may accelerate HIV disease
progression, resulting in declines in CD4 T-cell
counts, increased rates of infectious and
neoplastic opportunistic complications, and HIV-1
RNA breakthrough on HAART. Such acceleration may
be mediated through viral and/or host immunologic
pathways. - Alternatively, immunosuppression may result in
depletion of HIV-1 reservoirs or reductions in
viral rebound and improved HIV-related outcomes.
19Secondary Aim 2Explore the impact of
post-transplant immunosuppression on the
host-response to viral co-pathogens, including
hepatitis B and C, the human herpesviruses (CMV,
EBV, HHV-6, HHV-8) and HPV.
20Rationale
- The combination of immunosuppression and HIV
could alter viral activation and/or host immune
control of viruses that are associated with the
development of clinically significant disease
post-transplant.
21Secondary Aim 3Explore the impact of HIV
infection on the alloimmune response and
rejection rates.
22Rationale
- HIV transplant recipients may have perturbations
of the immune system that influence the immune
response to solid organ allografts that may have
implications for immunosuppression requirements.
23Secondary Aim 4Explore the pharmacokinetic
interactions between immunosuppressive agents and
the hepatically metabolized antiretroviral agents.
24Committees
- 1025 1040
- Michelle Roland
- Steering Committee
- Operations Committee
25(No Transcript)
26Steering Committee Key Responsibilities
- Approve protocol and any subsequent changes
- Approve the design and implementation of all
adjunct studies - Facilitate the conduct and monitoring of the main
trial and adjunct studies - Interpret study data safety and endpoint
- Oversee reporting of study results
- Recommend the addition or removal of sites
participating in the study based upon completion
of milestones
27Implementation and Performance
- The main trial and adjunct studies will be
implemented with approval of the Steering
Committee and the NIAID Program Officer - Sites will be required to accept and implement
the protocol and procedures approved by the
Steering Committee - Q6 month investigator meeting to consider
protocol revisions - SC will oversee mechanisms for assessing the
performance of each institution, with particular
attention to - accrual of adequate numbers of eligible subjects
- timely submission and quality of required data
- conscientious observance of protocol requirements
28Protocol Exemptions/Violations
- No exemptions to inclusion/exclusion criteria for
enrollment. - Protocol violations should be driven by patient
care needs. - Minimize as much as possible
- Report to IRB and NIH
- Will be reviewed by Steering Committee for
possible protocol modification - Use of investigational agents must be approved by
steering committee (MOP)
29Current Members
- Peter Stock and Michelle Roland
- Don Stablein Senior Biostatistician
- 2 Independent investigators To Be Named
- Robert Zackin and Debi Surlas Community
Representatives - 2 Daniella Livnat NIAID Program Officer
- Nancy Bridges DAIT Medical Officer
- Larry Fox DAIDS Medical Officer
- 1 John Fung and 1, 2 Margaret Ragni University of
Pittsburgh - 1, 2 Timothy Pruett, University of Virginia
1 Rotate yearly 2 Non-voting members
30Operations Committee
- Monthly teleconference
- Review safety reports (AE/SAE)
- Monitor site performance (accrual, follow-up, and
withdrawal) - Review protection of Human Subjects in research
- Address unanticipated problems
- Make recommendations concerning the protocol and
study performance to the Steering Committee for
approval
31Current Members
- Peter Stock and Michelle Roland
- Daniella Livnat NIAID Program Officer
- Nancy Bridges DAIT Medical Officer
- Larry Fox DAIDS Medical Officer
- Natasha Tomilin NIAID Project Manager
- Laurie Carlson UCSF Study Coordinator
- Rodney Rogers UCSF Project Manager
- Don Stablein Senior Biostatistician
32Stopping Rules
- 1040 - 1055
- Don Stablein
- Study Design and Control Groups
- Sample Size
- Monitoring
33Design Summary
- Protocol contains separate single arm evaluations
of - kidney transplant
- liver transplant
- Dual Primary Endpoints
- patient survival
- graft survival (death is an event)
34Sample Size
- 150 Kidney
- 125 Liver
- 3 Year accrual period
- Developed using a Sequential Probability Ratio
Test with 95 power for the specified hypotheses
of 1 year patient survival
35Developing the Hypotheses
- Anticipate patients may not do as well as
average, but believe results will be similar to
other high risk patients - Choose null using national data for a high risk
group- older (gt64 year old) patients - older patients have co-morbidities
- transplants are common
- outcome data are available
- Choose alternative using common delta
(difference) for both endpoints within organ
36Null and Alternative HypothesesOne Year Event
Rates
37DSMB Monitoring
- Construct upper confidence limit with 1-tailed
significance level of .0001 every 6 months. - Recommend stopping if the targeted national value
is not within the interval
38Operating Characteristics for Stopping
Guidelines Using Semi-Annual Confidence Limits
with .0001 1- Sided Significance Level. of
Trials Recommended for Stopping Prior to
Completing 3 Year Accrual Period, 2000 replicates
per cell
39Other Safety Monitoring
- Serious Adverse Events daily to co-PIs and NIH
Medical Officers - HIV Progression Alert Levels daily report to
Operations Committee - Viral Load new onset detectable or gt/ 1 log
increase - CD4 Count 25 decline w/o rejection therapy
- Other Adverse Events monthly
- Long term graft and patient survival
40Inclusion and Exclusion Criteria
- 1055 1110
- Michelle Roland
- Inclusion Criteria
- Exclusion Criteria
- Narrower Selection Criteria
41Key Inclusion Criteria
- Age gt 1 year old at Pediatric sites
- UCSF (L/K), University of Chicago (L), Mt. Sinai
(K), Columbia (L) - At non-pediatric sites age gt18
- CD4 T-cell count for past 6 months
- Kidney gt/ 200
- Liver gt/100 OR gt/ 200 if there is a history of
protocol allowed opportunistic complication - Use of IL-2 or GM-CSF in the prior six months to
increase CD4 counts is an exclusion
42Viral Load Must Be Undetectable for Subjects on
ARV Therapy
- lt 50 with Amplicor Monitor Ultrasensitive PCR or
- lt 75 with bDNA Versant version 3.0
- If other assays are used, co-PI will define
cut-off - Intermittent elevations to 1000 copies/mL, if not
persistent on more than 2 sequential measures and
followed by undetectable levels, are permitted
43Liver Subjects Who AreUnable to Tolerate ARV
Therapy
-
- May have detectable viral load if the study HIV
clinician confidently predicts HIV suppression
post-transplant - Based on ARV history, viral load while on ARVs,
adherence, and available resistance tests - If there is significant doubt about the ability
to suppress viral replication post-transplant,
the patient should not be enrolled
44ARV Use
- Kidney patients and liver patients currently
using antiretrovirals must be on stable ARV
regimen for at least 3 months prior to entry - OR
- Be able to maintain a persistently (always)
undetectable HIV-1 RNA level without ARVs - This criteria accounts for the very rare
long-term non-progressor with no history of
detectable HIV RNA
45OI History
- Per site policy, a history of the following
opportunistic infections or neoplasms may be
allowed if subjects have received appropriate
acute and maintenance therapy and have no
evidence of active disease. - Medical record documentation should be provided
by the primary medical provider whenever
possible.
46Specific OI Requirements for Enrollment
- Cryptococcal meningitis
- Requires negative serum CRAG
- Cytomegalovirus retinitis (CMV)
- No active disease on optho exam. Presence of an
intraocular implant does not imply active
disease. - Histoplasmosis
- Must be on or restart secondary prophylaxis
regardless of CD4 count. (Will be modified if
the USPHS/IDSA Guidelines re discontinuation of
secondary OI prophylaxis change.)
47Specific OI Requirements for Enrollment
- CNS Toxoplasmosis (Toxo)
- MRI without active disease
- Kaposis Sarcoma (KS)
- Clinical and radiologic evidence of complete
remission with immune reconstitution. No residual
cutaneous lesions and negative chest CT scan - HIV Encephalopathy (HIV Dementia)
- Resolved on HAART with marked improvement in
mental status and increased CD4 T-cell count and
no evidence of progression of CNS disease AND are
otherwise considered eligible from a functional
standpoint.
48Mycobacterial Infections
- Mycobacterium tuberculosis (TB)
- Completed standard treatment course
- Mycobacterium kansasii
- Completed standard treatment course
- Mycobacterium avium complex (MAC)
- Completion of 12 months of MAC therapy AND
negative MAC blood culture
49Key Exclusion Criteria OIs
- Progressive Mulitfocal Leukoencephalopathy (PML)
- Chronic Cryptosporidiosis (gt 1 month duration)
- Pulmonary Coccidiodomycosis will be treated per
local site policy in HIV negative transplant
candidates (generally 5-year disease-free
interval).
50Exclusion Criteria Neoplasms
- Lymphoma (Burkitts, immunoblastic or CNS)
- Any other neoplasm except
- cutaneous kaposis sarcoma
- in situ anogenital carcinoma
- adequately treated basal or squamous cell
carcinoma of the skin - solid tumors treated with curative therapy and
disease free for more than 5 years - hepatocellular carcinoma in liver candidates
51HCV Co-Infected Kidney Candidates
- Biopsy-documented cirrhosis requires listing for
combined liver and kidney transplant. - Exceptions will be made when sequential rather
than simultaneous transplant is appropriate, eg - ineligible for liver transplant due to medical
contraindications such as severe cardiopulmonary
disease - stable, compensated cirrhosis deemed by the
investigator to not necessitate transplant at
this time
52Narrower Selection Criteria
- Final decisions with regard to the application of
narrower selection criteria with regard to
pre-transplant viral load and history of
opportunistic complications are the prerogative
of the individual sites. However, individual
sites may not enroll patients who are outside the
bounds of the inclusion criteria.
53Schedule of Events
- 1110 1125
- Michelle Roland
- Clinical, Radiology, Laboratory (Safety, HIV,
Screening Serology) - Clusters/Sub-Studies
- HCV and HBV co-Infected Subjects
54Clinical and Radiology
55Laboratory
56(No Transcript)
57Clusters
- An administrative tool to distribute the burden
of additional lab studies among sites/subjects - Includes the site where the lab is
- Loosely geographically located
- Balance numbers to address aims
- Total blood volumes/storage blood calculated by
cluster
58Clusters
59Cluster 1 Sub-Studies Co-Pathogen
Virology/Immunology Transplant Immunology
60Cluster 1 Continued pK and HPV
61Cluster 2 Sub-Studies Co-Pathogen
Virology/Immunology
62Cluster 3 Sub-Studies HIVAN, HPV
63Cluster 4 Sub-Studies HPV
64HCV Subjects Virology and Immunology
1. Liver biopsy at month 6 post transplant then
annually. Kidney biopsy at month 6, year 2.5,
and year 5 if insurance is willing to cover. 2.
Liver subjects receiving HCV therapy must have
additional HCV RNA at 2, 6 and 12 months
post-therapy initiation. Kidney subjects
receiving HCV therapy must have additional HCV
RNA at 3 and 12 months post-therapy initiation.
65HBV Subjects Virology
66Questions and Answers
67Immunosuppressives
- 1230 1245
- Peter Stock
- Calcineurin Inhibitors
- CellCept
- Steroids
- Acute and Chronic Rejection
68Calcineurin Inhibitor
- Cyclosporine initial dose recommendations
- PI-containing regimen 25 50 mg PO BID.
- This also applies to combined PI-NNRTI-based
regimens - When used with a non-PI containing regimen 200
450 mg PO BID (200 mg if on Nevirapine 250 450
mg if on Efavirenz) - Tacrolimus initial dose recommendations
- PI-containing regimen 1 mg PO once to twice per
week. - This also applies to combined PI-NNRTI-based
regimens - When used with an non-PI-containing regimen 1 -
2 mg bid PO
69CellCept (MMF) and Steroids
- Standard dosing (1000 mg PO BID) will be
initiated in all kidney and liver subjects. - Dosing should be modified based on toxicity
(neutropenia, GI) and clinical judgment. - MMF may be tapered in stable liver transplant
recipients after 6 months of therapy. - Steroid induction, taper, and maintenance will be
according to local site practice.
70Notes
- Induction with an IL-2 receptor inhibitor
(anti-CD25 antibody) may be utilized for kidney
transplants, but no induction will be used for
liver transplants. - Immunosuppressant doses will be modified to
obtain routine trough levels standard for kidney
and liver transplants. - In the case of HIV disease progression,
immunosuppressive doses may be reduced to prevent
clinical decline.
71Notes
- The transplant team/study coordinator must be
notified of any change in immunosuppressive
dosing because there may be interactions with
antiretroviral drug dosing and visa versa. - Other agents to be used tx of acute and chronic
rejection - Sirolimus
- Anti-lymphocyte preparations (Thymoglobulin)
72Antiretrovirals and Resistance
- 1245 100
- Michelle Roland
- General Management Principals
- Responding to New Detectable Viral Load
- Resistance Testing
73Avoiding the Development of ARV Resistance
- Effective viral suppression requires multiple
ARVs - Viral resistance develops when the ARV regimen is
not potent enough - Inadequate number of different drugs
- Inadequate dose of drug
- Inadequate dosing schedule (eg missed doses)
- ARVs should be discontinued and restarted in
entire combinations, not parts of combinations
74Resistance Development
- HIV drug resistance can develop very quickly,
within days, for some drugs - Lamivudine (lamivudine) and all the NNRTIs
(efavirenz, nevirapine) - Cross resistance is a problem with all these
drugs - In the post-op period, it is best to hold all
ARVs until the patient is able to take pos,
there is no vomiting, and there are no tests
anticipated that will require an NPO period.
75Managing HBV and HIV Therapy
- In most cases, unless HIV drug resistance is
already present, HBV therapy should only be
initiated in combination with the full HIV ARV
combination (except HBIg) - This can be particularly complicated with
pre-transplant management in a patient with bad
liver disease in whom you want to avoid
hepatotoxins.
76New Detectable HIV Viral Load
- May be true failure to control HIV replication
and harbinger of breakthrough - May be a blip
- May be a false positive
- Recommend repeat ASAP so if it is a true and
persistent positive, the pros and cons of
modifying ARV therapy to minimize resistance
development can be considered
77Resistance Testing
- HIV Physician will determine when to request in
both screening and follow-up period - 2 types are available genotypic and phenotypic
- Main limitation is sensitivity
- Can only detect minority quasispecies gt 20 of
population - Drug selection pressure drives proportion of
quasispecies that will be resistant versus wild
type - Reversion to wild type does not mean resistant
virus is cleared - Can use to rule drugs out, but not to rule them
in - Second significant limitation is interpretation
of sequence/phenotype
78Prophylaxis
- 100 115
- Michelle Roland
- Transplant-Specific
- HIV-Specific
- Special Issues in Subjects with an OI History
(Recommendations from the MOP)
79Primary Prophylaxis
- Subject with no history of the disease
- At risk due to defined CD4 reduction or
transplantation - Standard prophylaxis recommendations
- Usually one drug
- Often discontinued when CD4 count is high enough
unless there is transplant associated risk (eg
PCP)
80Secondary Prophylaxis Chronic Maintenance
Therapy
- Subjects with a history of the disease
- Secondary prophylaxis should be reinstituted
- post- transplant for 1 month
- during treatment of acute rejection and for 1
month following completion of rejection therapy - if CD4 cell count drops below the defined level
- Secondary prophylaxis should be discontinued when
CD4 T-cell count is above the defined level for
six months - unless the patient is within one month of
completion of therapy for a rejection episode - These are often more intensive regimens than
primary prophylaxis regimens (eg usually 2
drugs).
81Pneumocystis Carinii Pneumonia (PCP)
- Primary and Secondary Prophylaxis are indicated
in all patients for life and should start
immediately post-transplant. - Preferred Regimen TMP-SMX DS or SS daily
- Alternatives TMP-SMX DS TIW, dapsone QD
(contraindicated if G6PD deficient), atovaquone
QD or aerosolized pentamidine monthly
82CMV Primary Prophylaxis
83CMV Secondary Prophylaxis
- CD4 cut-off 100 to start and gt/ 200 x 6
months to discontinue. - Preferred valcyte QD
- Alternative oral ganciclovir TID
84MAC Primary Prophylaxis
- CD4 T-cell count 75 to start and gt/ 100 x 6
months to discontinue. - Preferred Azithromycin weekly
- Alternatives clarithromycin BID (drug
interactions with immunosuppressive agents must
be considered). Because of the risk of rejection
due to drug interaction with calcinerin
inhibitors, rifabutin and rifampin should be
avoided for prophylaxis unless all other
alternatives have been exhausted.
85MAC Secondary Prophylaxis
- CD4 cut-off 75 to start and gt/ 100 x 6 months
to discontinue. - Preferred azithromycin QD plus ethambutol QD
plus leucovorin QD. - Alternatives replace azithromycin with
clarithromycin BID (drug interactions with
immunosuppressive agents must be considered).
Because of the risk of rejection due to drug
interaction with calcinerin inhibitors, rifabutin
and rifampin should be avoided for prophylaxis
unless all other alternatives have been
exhausted.
86Toxoplasmosis Primary Prophylaxis
- Toxo IgG-positive subjects with CD4 T-cell count
200. - Preferred DS TMP-SMX QD
- Alternatives SS TMP-SMX QD or atovaquone. If on
dapsone for PCP need to add pyrimethamine QD
leucovorin QD
87Toxoplasmosis Secondary Prophylaxis
- CD4 cut-off lt/ 200 to start gt 200 for 6 months
to discontinue - Preferred pyrimethamine QD plus sulfadiazine
QD plus leucovorin QD. - Separate PCP prophylaxis should be discontinued
if this regimen is used. - Alternative for patients who cannot tolerate
sulfa drugs pyrimethamine QD plus clindamycin
QID. - PCP prophylaxis must be continued with this
regimen.
88Cryptococosis Primary Prophylaxis
89Cryptococcosis Secondary Prophylaxis
- CD4 cut-off lt/ 200 to start gt 200 for 6 months
to discontinue - Preferred fluconazole qD (200 mg)
- Severe toxicity from calcineurin inhibitors may
result if daily fluconazole (or another azole) is
used - The dose of calcineurin inhibitors should be
reduced by 50 sometimes more significant dose
reduction is required. - Daily calcineurin inhibitor trough levels should
be monitored during the first week of therapy, or
longer if necessary. - Similar adjustments are required in the dosing of
sirolimus and tacrolimus.
90Histoplasmosis Primary Prophylaxis
91Histoplasmosis Secondary Prophylaxis
- Prophylaxis must be continued regardless of CD4
count until DHHS guidelines are modified to
recommend a safe level for discontinuation - Preferred itraconazole DD
- Alternatives high dose fluconazole (400 mg) QD
- Severe toxicity from calcineurin inhibitors may
result if daily azoles are used
92Candidiasis
- Per site practice, but fluconazole 100mg once per
week for 3 months, supplemented with Mycelex
troches, is highly recommended. - Severe toxicity from calcineurin inhibitors may
result if daily fluconazole (or another azole) is
used -
- See previous recommendations for dose adjustments
93EBV Prophylaxis
- Indicated for EBV negative recipient with
positive donor. - Regimen IV ganciclovir QD while hospitalized
then, ganciclovir PO TID x 1 year. - Patients should not be continued on acyclovir if
they are on ganciclovir.
94Anticipated Drug Interactions/Dosing
- 115 130
- Laurie Carlson
- Protease Inhibitors and Calcineurin Inhibitors
- NNRTIs
95Dosing of Protease Inhibitors with Calcineurin
Inhibitors
96Dosing of NNRTIs with Calcineurin Inhibitors
97Dosing of PI NNRTIs Combinations with
Calcineurin Inhibitors
98Dosing of Antiretrovirals with Sirolimus
99Factors Influencing Dosing
- Graft function
- Initiation of ARV therapy post transplant
- Tenofovir and renal insufficiency
- Side effects
- Education
100Questions and Answers
101HCV Co-Infected Patients
- 200 220
- Peter Stock
- Liver Patients
- Kidney Patients
102Treatment of HCV Liver Recipients When?
- HCV treatment will not be initiated preemptively
post-transplant - No data to suggest that HCV RNA clearance rates
are higher - Minimize drug interactions and toxicity in the
early post-transplant period - HCV treatment will be initiated if biopsy shows
severe or progressive recurrent HCV disease - HAI scoregt 8 and/or fibrosis stage gt2 are
considered indications for treatment by most
transplant physicians but the decision to treat
will ultimately be determined by the treating
physician.
103Biopsies in HCV Liver Recipients When to Do?
Who Reads?
- Protocol biopsies 6 and 12 months post
transplant, then annually - And at any time as clinically indicated
- Treatment decisions based upon local pathologist
reading - For outcomes determinations, biopsies will be
read by a central pathologist and will be scored
using the Ishak version of Knodell
104HCV Treatment Regimen
- Peg-INF or standard INF plus ribavirin.
- Not altered based upon prior INF experience or
genotype. - Peg-INF a-2b 1.0-1.5 ug/kg or Peg-INF a-2a 180 ug
weekly - Start at half dose
- Increase to full-dose in 2 weeks if blood counts
are acceptable - Ribavirin 200 mg PO BID x 2 weeks, then 400 mg PO
BID x 2 weeks if tolerated, then 10-13 mg-kg as
divided dose if tolerated. - Transplant patients have renal clearance issues
that make increasing ribavirin dose too high
and/or too quickly result in drug-limiting
anemia. Thus, ribavirin should be titrated up
slowly as tolerated.
105Monitoring on HCV Treatment
- Pre-therapy CBC, liver, renal, TSH, lipids,
CXR, EKG - Months 1-2 post-therapy initiation weekly
CBC - Months 3, 6, 9, 12 post-therapy initiation TSH
- HCV RNA all HCV co-infected patients have
baseline, month 3, 6, 12 and years 2 and 5. - Subjects receiving HCV therapy have additional
HCV RNA at 2, 6 and 12 months post-therapy
initiation. - Depression screen monthly for first 3 months,
then every 3 months. - Patients should be provided with 24-hour clinical
contact number for adverse effect notification.
106Length of Treatment
- 12 month minimum. At 12 months, response will be
determined by measurement of HCV RNA (if
quantitative negative, will do qualitative),
AST/ALT and liver histology. - Types of Response and Actions
- HCV RNA negative at 6 and 12 months stop
treatment - HCV RNA positive but liver histology improved
stop treatment. Consider re-initiation of
therapy if disease activity (histology,
biochemical) increases. - HCV RNA positive but liver histology unchanged or
worse Continue treatment for another 12 months
(or consider for experimental therapies).
107 Marrow-Supportive Therapy
- Erythropoietin
- Start when hemoglobin is lt10g/dl.
- Dose 40,000 IU subcutaneously weekly.
- If hemoglobin decreases below 8.0 g/dL,
discontinue ribavirin until gt10 g/dL (women) or
gt12 g/dL (males) on erythropoietin. If ribavirin
is restarted, use 50 of the dose used when
ribavirin was discontinued. - G-CSF
- Start when ANC is lt1,000/mm3.
- Dose 300 ug twice weekly. If subsequent trough
ANC gt3000/mm3, reduce dose to 150 ug twice weekly
or 300 ug once weekly. Continued until the end
of treatment.
108Pre-Transplant Treatment of HCV Kidney
Candidates When?
- Pre-transplant therapy with interferon/peg-interfe
ron will be considered in each patient but is not
required. - Pre-transplant therapy is strongly recommended
if - Biopsy shows stage stage 2 or greater disease
- All patients with non-1 genotypes, regardless of
stage of disease, since the viral clearance rates
with INF treatment are gt50 for this subgroup. -
109Post-Transplant Treatment of HCV Kidney
Recipients When?
- Advanced or progressive liver disease
post-transplant will be targeted for anti-HCV
treatment - Post-transplantation therapy will be offered but
not required in the following circumstances - Biopsy evidence of progressive disease (increase
in fibrosis score) - Any biopsy showing stage 3 or 4 disease
- Biopsy and clinical features of fibrosing
cholestatic hepatitis
110Biopsies in HCV Kidney Recipients When to Do?
Who Reads?
- Pre-transplant assess histological stage rule
out cirrhosis - Protocol biopsies month 6, year 2.5, and year 5
(use GCRC) - At any time for clinical indications
- AST or ALT gt2 ULN for gt/ 3 months
- significant change in AST, ALT, alkaline
phosphatase or total bilirubin from baseline in
order to rule out concurrent conditions (e.g.
drug toxicity, biliary disease, fibrosing
cholestatic hepatitis or other progressive HCV
disease). - Treatment decisions based upon local pathologist
reading - For outcomes determinations, biopsies will be
read by a central pathologist and will be scored
using the Ishak version of Knodell
111HCV Treatment Regimen
- Pre-transplant Peg- INF or standard INF
- not altered based upon prior INF experience
- standard INF 3 million units three times weekly
- pegylated INF 1.0-1.5 ug/kg (peg-INF alfa-2b)
weekly or 180 ug weekly (peg-INF alfa-2a). - Post-transplant Peg-INF or standard INF plus
ribavirin.
112Monitoring on HCV Treatment
- Same as in liver recipients
113Length of HCV TreatmentPre-Transplant
- Minimum of 3 months
- At 3 months, if a 2-log reduction in HCV RNA or
HCV RNA negative, continued for a total of 6 to
12 months (depending upon genotype and stage of
fibrosis). - If the patient does not achieve at least a 2-log
reduction in HCV RNA by month 3 of treatment, the
treatment will be discontinued. - Note liver and combined kidney-liver candidates
- will not be encouraged to treat HCV
pre-transplant (as kidney candidates are) as it
is assumed that they have already exhausted all
medical therapy options for the treatment of HCV.
114Length of Treatment Post-Transplant
- 12 months. HCV RNA at 3 and 12 months
post-therapy (if quantitative negative at 12
months, will do qualitative - Repeat biopsy following 12 months of treatment
recommended - Types of Response and Actions
- HCV RNA negative at end of treatment stop and
observe for relapse. - HCV RNA positive at end of treatment stop and
observe for histological progression. - Consider re-initiation of therapy if histological
activity or fibrosis score increases.
115Marrow-Supportive Therapy
- EPO and G-CSF as for liver recipients
116HBV Co-Infected Patients
- 220 230
- Peter Stock
- Liver Patients
- Kidney Patients
117Biopsies Liver and Kidney Recipients
- No protocol-mandated biopsies
- Biopsies should be obtained if
- AST or ALT gt 1.5 ULN
- Any HBV virological breakthrough
- Suspicion of drug hepatotoxicity
118Treatment Guidelines for Liver and Kidney
Candidates Pre-Transplant
- If lamivudine naïve, treat with lamivudine 150mg
BID - May use lamivudine plus adefovir or tenofovir
- If lamivudine resistant, use tenofovir or
adefovir plus lamivudine - (Emtriva FTC has not been added to protocol
yet)
119Treatment Guidelines for Liver and Kidney
Recipients Peri-Transplant
- Continue lamivudine, adefovir or tenofovir as
prescribed pre-transplant - Adjust for renal function
- If unable to start HIV antiretroviral therapy
post-transplant, hold HBV antiviral medication
until able to start HIV antiretroviral therapy
120Treatment Guidelines for Liver Recipients
Peri-Transplant
- HBIg Dosing Schedule 10,000 IU during the
anhepatic phase and on admission to ICU. 5,000
IU Q6 hours for days 1 and 2 post-op, and 10,000
IU daily for days 3 7 post-op. Check HBsAg on
day 2 and if positive, give 10,000 IU every 12
hours until HbsAg negative. - If patient is HBV DNA detectable pre liver
transplant, closer monitoring of HBIG dosing is
advised, especially if HBV antivirals are on
hold. - If HBV antivirals are held, check HbsAg daily and
continue 5000 IU Q6 hours until HbsAg is
negative, then 10,000 IU daily for 7 days of
treatment.
121HBV Treatment Guidelines for Liver Recipients
Post-Transplant
- Continue HBV and HIV antiretrovirals indefinitely
- HBIG
- 10,000 IU monthly for 3 months, then
- 5,000 IU for next 3 months, then
- 2,500 IU (IM or IV) monthly thereafter,
indefinitely - Monitor HBsbAg and anti-HBs titer monthly.
- Monitor HBV DNA levels as clinically indicated
(AST or ALT gt 1.5 ULN) and every 3 months.
122Treatment Guidelinesfor Kidney Recipients
Post-Transplant
- If patient has stage 3 or 4 fibrosis, antiviral
therapy should be continued indefinitely - For patients with lt/ stage 2 fibrosis, antiviral
therapy can be stopped after 12 months if the
following criteria are met - Normal liver enzymes
- Minimal (5 mg QD or QOD) or no prednisone
- No recent change in immunosuppression (stable for
preceding 3 months)
123Treatment Guidelinesfor Kidney Recipients
Restarting HBV Therapy
- Restart HBV therapy and continue indefinitely if
AST or ALT increase to gt 1.5 ULN and HBV DNA gt
105 copies/mL after treatment is stopped. - Additionally, give HBV antiviral therapy whenever
a patient receives treatment for rejection
continue for at least 4 months stop only when - Normal liver enzymes
- Minimal (5 mg QD or QOD) or no prednisone
- No recent change in IMS (stable for preceding 3
months)
124Monitoring Guidelines Liver and Kidney
Recipients
- Pre-transplant HBV DNA every 3 months
- Peri-transplant HBV DNA immediately
pre-transplant. - Post-transplant In addition to the
protocol-mandated labs, it is recommended for
clinical management that HBV DNA be followed
every 3 months and as clinically indicated (AST
or ALT gt 1.5 ULN) and that HBSAg and HBSAb be
followed monthly
125Rejection
- 230 245
- Peter Stock
- Management
- Definitions
126Acute and Chronic Rejection
- A biopsy will be performed in all cases of
suspected rejection - Therapy may be initiated lt/ one day prior to the
results of the biopsy if clinically indicated. - Treatment for gt 1 day, including increases in
the dose of immunosuppressive medications, cannot
be sustained without a biopsy, unless the
managing physicians believe biopsy is unsafe. - Treatment of rejection episodes will be according
to local site practices and may include
sirolimus. - OKT3 and polyclonal anti-lymphocyte preparations
have resulted in prolonged reduction in CD4
counts in HIV infected transplant recipients, and
their use should be restricted to treatment for
severe rejection.
127Definition of Rejection
- Kidney (NIH CCTT Definition)
- Type I mononuclear infiltrate in gt or 5 of
cortex, a total of at least three tubules with
tubulitis in 10 consecutive high-power fields
from the most severely affected areas, and at
least two of the three following features edema,
activated lymphocytes, or tubular injury. - Type II arterial, or arteriolar, endothelialitis
with or without the preceding features. - Type III arterial fibrinoid necrosis or
transmural inflammation with or without
thrombosis, parenchymal necrosis, or hemorrhage. - Liver (Banff Criteria)
- Liver rejection will be defined by the Banff
global grading scheme and Banff rejection
activity index.
128Questions and Answers
129Adverse Event Reporting
- 310 325
- Natasha Tomlin
- TBD
130Data Management
131Website Modifications
- Updated sample letter requesting reimbursement
- Updated PDFs for relevant studies
- Updated contact list of experienced folks willing
to help
132Publication and Media Policy
- 345 355
- Michelle Roland
- Membership
- Roles
133PPSC Membership
- 1 from each Clinical Site
- Balance transplant and HIV
- PI discuss with key personnel and elect
- 1 from each Lab Site
- 1 from CAB
- Add expertise as needed for concepts
- PPSC elects its chair
134PPSC Roles
- Specific roles and procedures to be determined by
PPSC - Guiding principles
- Old Ideas New Ideas
- Multi-Site Study Aim PI Concept Sheet
(encouraged) - Single Site Concept Sheet None Required
- (discouraged) (requested)
135Reimbursement Considerations
- 355 410
- Peter Stock, Cheryl Janov
136Who Paid in Pilot Multi-Site Study?
- Kidney recipients
- 69 Medicare
- 8 Medicaid
- 23 Private Insurers
- Liver recipients
- 10 Medicare
- 20 Medicaid
- 40 Private Insurers
- 30 CA Research Funds
137Website
- Sample letters to insurers
- Supporting articles to include with coverage
request
138IRB Re Experimental
- The procedure is not experimental
- The population/context is
139Donor Consent
- Required at each site
- Must include disclosure of candidate HIV status
prior to invasive procedures in donor - Alternatives cadaver donor, off-study transplant
140Community Advisory Board
- 410 420
- Michelle Roland, Debi Surlas and Robert Zackin
- TBD
141Closing Discussion
142Parking Lot Issues from SC
- Pre-eligible consent/enrollment for outcomes
- Specimen request review process